Tubize-Fin (TUB) - Total Liabilities
Based on the latest financial reports, Tubize-Fin (TUB) has total liabilities worth €48.58 Million EUR (≈ $56.79 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Tubize-Fin net asset momentum to track the company's year-over-year net asset growth rate.
Tubize-Fin - Total Liabilities Trend (2000–2025)
This chart illustrates how Tubize-Fin's total liabilities have evolved over time, based on quarterly financial data. See TUB free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Tubize-Fin Competitors by Total Liabilities
The table below lists competitors of Tubize-Fin ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Confluent Inc
NASDAQ:CFLT
|
USA | $1.82 Billion |
|
JAPAN EX UN.ADR 1/2 O.N.
F:OSKU
|
Germany | €78.82 Trillion |
|
Petronas Chemicals Group Bhd
KLSE:5183
|
Malaysia | RM20.58 Billion |
|
Addtech AB (publ.)
ST:ADDT-B
|
Sweden | Skr10.80 Billion |
|
Hubei Dinglong Chemical
SHE:300054
|
China | CN¥3.97 Billion |
|
Anker Innovations Technology Co Ltd
SHE:300866
|
China | CN¥9.91 Billion |
|
The Federal Bank Limited
NSE:FEDERALBNK
|
India | Rs3.61 Trillion |
|
Semiconductor Manufacturing Electronics (Shaoxing) Corp. A
SHG:688469
|
China | CN¥13.49 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Tubize-Fin's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Tubize-Fin worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tubize-Fin's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tubize-Fin (2000–2025)
The table below shows the annual total liabilities of Tubize-Fin from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €48.58 Million ≈ $56.79 Million |
-45.59% |
| 2024-12-31 | €89.28 Million ≈ $104.37 Million |
-27.80% |
| 2023-12-31 | €123.65 Million ≈ $144.56 Million |
+41.82% |
| 2022-12-31 | €87.19 Million ≈ $101.93 Million |
+316.40% |
| 2021-12-31 | €20.94 Million ≈ $24.48 Million |
-38.88% |
| 2020-12-31 | €34.26 Million ≈ $40.05 Million |
-60.83% |
| 2019-12-31 | €87.46 Million ≈ $102.25 Million |
-39.28% |
| 2018-12-31 | €144.04 Million ≈ $168.40 Million |
-26.38% |
| 2017-12-31 | €195.65 Million ≈ $228.74 Million |
-26.24% |
| 2016-12-31 | €265.26 Million ≈ $310.12 Million |
-14.94% |
| 2015-12-31 | €311.84 Million ≈ $364.57 Million |
+46.03% |
| 2014-12-31 | €213.55 Million ≈ $249.66 Million |
-15.67% |
| 2013-12-31 | €253.23 Million ≈ $296.05 Million |
-13.73% |
| 2012-12-31 | €293.53 Million ≈ $343.17 Million |
-8.36% |
| 2011-12-31 | €320.31 Million ≈ $374.48 Million |
-6.06% |
| 2010-12-31 | €340.97 Million ≈ $398.63 Million |
-7.00% |
| 2009-12-31 | €366.64 Million ≈ $428.64 Million |
-5.97% |
| 2008-12-31 | €389.92 Million ≈ $455.86 Million |
-5.77% |
| 2007-12-31 | €413.79 Million ≈ $483.77 Million |
+72.19% |
| 2006-12-31 | €240.31 Million ≈ $280.95 Million |
+104.48% |
| 2005-12-31 | €117.52 Million ≈ $137.40 Million |
-4.22% |
| 2004-12-31 | €122.70 Million ≈ $143.44 Million |
-21.41% |
| 2003-12-31 | €156.12 Million ≈ $182.52 Million |
-8.94% |
| 2002-12-31 | €171.45 Million ≈ $200.44 Million |
+33.07% |
| 2001-12-31 | €128.84 Million ≈ $150.63 Million |
+57.37% |
| 2000-12-31 | €81.87 Million ≈ $95.72 Million |
-- |
About Tubize-Fin
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.